6H05 (TFA)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

6H05 (TFA)  纯度: 99.55%

6H05 TFA 是突变型原癌基因K-ras(G12C)选择性变构抑制剂。

6H05 (TFA)

6H05 (TFA) Chemical Structure

CAS No. : 2061344-88-3

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥1805 In-stock
2 mg ￥926 In-stock
5 mg ￥1390 In-stock
10 mg ￥2450 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

6H05 (TFA) 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Kinase Inhibitor Library
  • Anti-Cancer Compound Library
  • Covalent Screening Library
  • Ferroptosis Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Angiogenesis Related Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

6H05 TFA is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C). IC50 value: Target: K-Ras G12C 6H05 gives the greatest degree of modification, which allosterically modifies the oncogenic G12C mutant of highly homologous protein H-Ras without affecting wild-type K-Ras [1]. 6H05 can be used as an intermediate for the synthesis of other oncogenic K-Ras(G12C) inhibitors [2].

分子量

590.14

Formula

C22H31ClF3N3O4S3
CAS 号

2061344-88-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

DMSO : ≥ 51 mg/mL (86.42 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.6945 mL 8.4726 mL 16.9451 mL
5 mM 0.3389 mL 1.6945 mL 3.3890 mL
10 mM 0.1695 mL 0.8473 mL 1.6945 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Ostrem JM, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013 Nov 28;503(7477):548-51.

    [2]. Lu S, et al. Harnessing allostery: a novel approach to drug discovery. Med Res Rev. 2014 Nov;34(6):1242-85.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务